Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung
New data for AMG 510 at ESMO show the drug is more active in lung than colorectal cancer, as was reported at ASCO, but Amgen's Greg Friberg notes that Phase I monotherapy and planned combination studies may shed more light on KRAS biology and efficacy in different tumor types.
You may also be interested in...
Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.